[go: up one dir, main page]

SE9903997D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9903997D0
SE9903997D0 SE9903997A SE9903997A SE9903997D0 SE 9903997 D0 SE9903997 D0 SE 9903997D0 SE 9903997 A SE9903997 A SE 9903997A SE 9903997 A SE9903997 A SE 9903997A SE 9903997 D0 SE9903997 D0 SE 9903997D0
Authority
SE
Sweden
Prior art keywords
compounds
new compounds
nicotinic
reductions
enantiomers
Prior art date
Application number
SE9903997A
Other languages
English (en)
Inventor
David Gurley
Thomas Lanthorn
John Macor
James Rosamond
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903997A priority Critical patent/SE9903997D0/sv
Publication of SE9903997D0 publication Critical patent/SE9903997D0/sv
Priority to KR1020027005706A priority patent/KR20020063176A/ko
Priority to CNB008154414A priority patent/CN1239482C/zh
Priority to PCT/SE2000/002148 priority patent/WO2001032619A1/en
Priority to MXPA02004232A priority patent/MXPA02004232A/es
Priority to BR0015195-5A priority patent/BR0015195A/pt
Priority to JP2001534771A priority patent/JP2003513071A/ja
Priority to NZ530161A priority patent/NZ530161A/en
Priority to CO00083175A priority patent/CO5251458A1/es
Priority to US10/111,027 priority patent/US6750242B1/en
Priority to NZ518450A priority patent/NZ518450A/en
Priority to AU14264/01A priority patent/AU783507B2/en
Priority to EP00976500A priority patent/EP1230216A1/en
Priority to IL14909800A priority patent/IL149098A0/xx
Priority to CA002387745A priority patent/CA2387745A1/en
Priority to ZA200203171A priority patent/ZA200203171B/xx
Priority to NO20022009A priority patent/NO323076B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9903997A 1999-11-03 1999-11-03 New compounds SE9903997D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds
CA002387745A CA2387745A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
JP2001534771A JP2003513071A (ja) 1999-11-03 2000-11-01 ニコチン受容体作用薬の正のモジュレーター
CO00083175A CO5251458A1 (es) 1999-11-03 2000-11-01 Nuevos compuestos
PCT/SE2000/002148 WO2001032619A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
MXPA02004232A MXPA02004232A (es) 1999-11-03 2000-11-01 Moduladores positivos de agonistas de receptores nicotinicos.
BR0015195-5A BR0015195A (pt) 1999-11-03 2000-11-01 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
KR1020027005706A KR20020063176A (ko) 1999-11-03 2000-11-01 니코틴 수용체 작용물질의 양성 조절자
NZ530161A NZ530161A (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
CNB008154414A CN1239482C (zh) 1999-11-03 2000-11-01 烟碱性受体激动剂的正调节剂
US10/111,027 US6750242B1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
NZ518450A NZ518450A (en) 1999-11-03 2000-11-01 Indole derivatives and their use as positive modulators of nicotinic receptor agonists
AU14264/01A AU783507B2 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
EP00976500A EP1230216A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
IL14909800A IL149098A0 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists
ZA200203171A ZA200203171B (en) 1999-11-03 2002-04-22 Positive modulators of nicotinic receptor agonists.
NO20022009A NO323076B1 (no) 1999-11-03 2002-04-26 Forbindelser, preparater, nevnte forbindelser og preparater for bruk i terapi samt anvendelse av nevnte forbindelser for fremstilling av preparater til medisinsk behandling.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds

Publications (1)

Publication Number Publication Date
SE9903997D0 true SE9903997D0 (sv) 1999-11-03

Family

ID=20417607

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds

Country Status (16)

Country Link
US (1) US6750242B1 (sv)
EP (1) EP1230216A1 (sv)
JP (1) JP2003513071A (sv)
KR (1) KR20020063176A (sv)
CN (1) CN1239482C (sv)
AU (1) AU783507B2 (sv)
BR (1) BR0015195A (sv)
CA (1) CA2387745A1 (sv)
CO (1) CO5251458A1 (sv)
IL (1) IL149098A0 (sv)
MX (1) MXPA02004232A (sv)
NO (1) NO323076B1 (sv)
NZ (2) NZ530161A (sv)
SE (1) SE9903997D0 (sv)
WO (1) WO2001032619A1 (sv)
ZA (1) ZA200203171B (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003265842A1 (en) 2002-08-30 2004-03-19 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
EP2336128A1 (en) 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
EA013123B1 (ru) 2005-04-13 2010-02-26 Ньюрэксон, Инк. Замещенные индолы, обладающие активностью ингибирования nos
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
TW200808780A (en) * 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
US20090163451A1 (en) * 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
WO2009062319A1 (en) 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
CN101990537A (zh) * 2008-02-07 2011-03-23 雅培制药有限公司 作为阳性别构调节剂的酰胺衍生物和其使用方法
CN102066356B (zh) * 2008-04-17 2014-06-11 葛兰素集团有限公司 作为α7烟碱型乙酰胆碱受体亚型调节剂的吲哚衍生物
NZ596390A (en) * 2009-04-16 2013-08-30 Proximagen Ltd Indole derivative modulators of the alpha 7 nachr
AU2011256287B2 (en) * 2010-05-17 2016-11-10 Envivo Pharmaceuticals, Inc. A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
KR102242658B1 (ko) * 2018-08-29 2021-04-21 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787551A (en) * 1954-02-24 1957-04-02 Eastman Kodak Co Compositions stabilized with hydroxyindole
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
WO1993011106A1 (en) * 1991-11-25 1993-06-10 Pfizer, Inc. Indole derivatives
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
MXPA02004232A (es) 2002-10-17
CA2387745A1 (en) 2001-05-10
KR20020063176A (ko) 2002-08-01
EP1230216A1 (en) 2002-08-14
US6750242B1 (en) 2004-06-15
NO20022009D0 (no) 2002-04-26
NO323076B1 (no) 2006-12-27
WO2001032619A1 (en) 2001-05-10
IL149098A0 (en) 2002-11-10
CN1387512A (zh) 2002-12-25
CN1239482C (zh) 2006-02-01
CO5251458A1 (es) 2003-02-28
AU1426401A (en) 2001-05-14
AU783507B2 (en) 2005-11-03
NZ518450A (en) 2004-04-30
NZ530161A (en) 2005-08-26
BR0015195A (pt) 2002-06-18
JP2003513071A (ja) 2003-04-08
ZA200203171B (en) 2003-09-23
NO20022009L (no) 2002-07-02

Similar Documents

Publication Publication Date Title
SE9903998D0 (sv) New compounds
SE9903997D0 (sv) New compounds
SE9903760D0 (sv) New compounds
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MY134568A (en) Cb2 receptor agonists
SE9904176D0 (sv) New use
AU2002246728A1 (en) Carboline derivatives
ATE316083T1 (de) Adamantanderivate
IS6520A (is) Ný efnasambönd
MY137156A (en) Dual nk1/nk3 derivatives
SE9900961D0 (sv) Novel compounds
SE0402762D0 (sv) Indazole sulphonamide derivatives
AU2002249890A1 (en) Carboline derivatives
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE9802208D0 (sv) Novel compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
GB0109122D0 (en) Novel compounds
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
EP1109560A4 (en) COMPOUNDS USEFUL AS AICARFT INHIBITORS
SE9802209D0 (sv) Novel compounds
AU2002359150A8 (en) Therapeutic heterocycles
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
SE9903996D0 (sv) New compounds